王文龙 - 江南大学

个人简介

1994.09～1998.07 杭州师范大学化学教育专业，获理学学士学位。1998.08～2000.08杭州市保俶塔实验学校，化学教师。2000.09～2005.08 中国科学院上海药物研究所，药物化学专业，获理学博士学位。2005.09～2006.08 美国伊利诺依大学芝加哥分校药学院，博士后。2006.09～2008.12 美国印地安纳大学医学院，博士后。2009.01～2010.07 美国Bioduro公司高级研发经理。2010.08～2012.02杭州特创生物技术有限公司，执行总监。2012.03～2018.05 江南大学药学院副教授，硕士生导师，2018.06～至今江南大学药学院药学系教授、硕士生导师、药学系主任。

研究领域

主要从事重大疾病治疗创新药物研发，重点研究蛋白酪氨酸磷酸酶家族（PTPs）小分子先导化合物发现与结构优化，以及药物合成新工艺与新方法

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

[1] Synthesis and biological evaluation of novel bis-aromatic amides as novel PTP1B inhibitor. Bioorganic & Medicinal Chemistry Letters. 2018, 24, 1889–1894. [2] Decoquinate derivatives: A new class of potent antischistosomal agents against Schistosoma japonicum. Chinese Chemical Letters. 2017, 28(7), 1547-1552. [3] Synthesis of Aromatic Amide Derivatives and Their Biological Evaluation against Protein Tyrosine Phosphatase 1B and Scr Homology-2 Domain Containing Protein Tyrosine Phosphatase-2. Chinese. Journal of Organic Chemistry. 2016, 36(9), 2142-2149. [5] Synthesis of Novel 3-aryl-1-oxa-2,8-diazaspiro [4.5]dec-2-ene Derivatives and Their Biological Evaluation Against Protein Tyrosine Phosphatase 1B. Chemical Biology & Drug Design 2015, 86(5), 1161–1167. [6] Synthesis and biological evaluation of novel bis-aromatic amides as novel PTP1B inhibitors. Bioorganic & Medicinal Chemistry Letters 2014, 24, 1889-1894. [7] 1H-2,3-Dihydroperimidine Derivatives: A New Class of Potent Protein Tyrosine Phosphatase 1B Inhibitors. Molecules. 2014, 19, 102-121. [8] Synthesis and evaluation of the antischistosomal activity against S. japonicum of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives. Chinese. Journal of Organic Chemistry. 2013, 33, 2588-2599. [9] Synthesis and SAR studies of praziquantel derivatives with activity against Schistosoma japonicum. Molecules. 2013, 18(8), 9163-9178. [10] Synthesis and antiviral activity of conformational analogues of leucamide A. Molecules. 2012, 17(12), 14522-14530. [11] Synthesis and biological evaluation of salicylate-based compounds as a novel class of methionine aminopeptidase inhibitors. Bioorganic & Medicinal Chemistry Letters. 2011, 21(23), 7151-7154. [12] Inhibition of Mycobacterium tuberculosis Methionine Aminopeptidases by Bengamide Derivatives. ChemMedChem. 2011, 6, 1041-1048. [13] Growth inhibition of Escherichia coli and methicillin-resistant Staphylococcus aureus by targeting cellular methionine aminopeptidase. European Journal Medicinal Chemistry 2011, 46, 3537-3540. [14] Searching for Disease Modifiers - PKC Activation and HDAC Inhibition - A Dual Drug Approach to Alzheimer’s Disease that Reduces Aβ Production while Blocking Oxidative Stress. ChemMedChem. 2009, 4, 1095-1105. [15] Synthesis and structure-function analysis of Fe(II)-form-selective antibacterial inhibitors of Escherichia coli methionine aminopeptidase, Bioorganic & Medicinal Chemistry Letters. 2009, 19, 1080-1083. [16] Fe(II) is the native cofactor for Escherichia coli methionine aminopeptidase. Journal of Biological Chemistry. 2008, 283, 26879-26885. [17] Discovery of inhibitors of Escherichia coli methionine aminopeptidase with the Fe(II)-form selectivity and antibacterial activity. Journal of Medicinal Chemistry. 2008, 51, 6110-6120. [18] Discovery and Structural Modification of Inhibitors Of Human Hepatitis B Virus inspired from marine natural product Leucamide A. ChemMedChem. 2008, 3, 1316-1321. [19] Synthesis and biological evaluation of novel bisheterocycle-containing compounds as potential anti-influenza virus agents. Bioorganic & Medicinal Chemistry Letters. 2005, 15(23), 5284-5287. [20] First total synthesis of leucamide A. Journal of Organic Chemistry. 2003, 68(4), 1636-1639.